References: Monitoring and titrating antipsychotic therapy for a first episode of psychosis
Agid O, Schulze L, Arenovich T, Sajeev G, McDonald K, Foussias G, et al. Antipsychotic response in first-episode schizophrenia: efficacy of high doses and switching. Eur Neuropsychopharmacol 2013;23(9):1017–22. https://www.ncbi.nlm.nih.gov/pubmed/23706529
Galletly C, Castle D, Dark F, Humberstone V, Jablensky A, Killackey E, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Aust N Z J Psychiatry 2016;50(5):410–72. https://www.ncbi.nlm.nih.gov/pubmed/27106681
Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry 2012;13(5):318–78. https://www.ncbi.nlm.nih.gov/pubmed/22834451
Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry 2018;51(1-02):9–62. https://www.ncbi.nlm.nih.gov/pubmed/28910830
Kane JM, Schooler NR, Marcy P, Correll CU, Achtyes ED, Gibbons RD, et al. Effect of long-acting injectable antipsychotics vs usual care on time to first hospitalization in early-phase schizophrenia: A randomized clinical trial. JAMA Psychiatry 2020. https://www.ncbi.nlm.nih.gov/pubmed/32667636
National Institute for Health and Care Excellence (NICE). Psychosis and schizophrenia in adults: prevention and management [cg178]. London: NICE; 2014. https://www.nice.org.uk/guidance/cg178
